LEM domain containing 1 promotes thyroid cancer cell proliferation and migration by activating the Wnt/β‑catenin signaling pathway and epithelial‑mesenchymal transition

Xu,Min; Lin,Bangyi; Zheng,Danni; Wen,Jialiang; Hu,Wenjing; Li,Chunxue; Zhang,Xianwei; Zhang,Xiaohua; Qu,Jinmiao

doi:10.3892/ol.2021.12703

LEM domain containing 1 promotes thyroid cancer cell proliferation and migration by activating the Wnt/β‑catenin signaling pathway and epithelial‑mesenchymal transition

Authors:
- Min Xu
- Bangyi Lin
- Danni Zheng
- Jialiang Wen
- Wenjing Hu
- Chunxue Li
- Xianwei Zhang
- Xiaohua Zhang
- Jinmiao Qu
View Affiliations

Affiliations: Department of Operating Theatre, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China, Department of Thyroid Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China
Published online on: April 2, 2021 https://doi.org/10.3892/ol.2021.12703
Article Number: 442
Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Thyroid cancer (TC) is the most common type of endocrine malignancy in humans, and its relative incidence has increased continuously in recent years. However, the primary molecular mechanisms of thyroid tumorigenesis and progression remain unclear. Papillary TC (PTC) is the most common subtype of TC. Recent studies have reported that one of the tumorigenesis and progression mechanisms is driven by genetic alterations that regulate the TC cell signaling pathway. In the present study, RNA sequencing (RNA‑seq) was performed on 79 paired PTC and adjacent normal thyroid tissues to further study the molecular mechanisms of TC. Reverse transcription‑quantitative PCR was used to detect the expression levels of LEM domain containing 1 (LEMD1) in 47 paired PTC and adjacent normal thyroid tissue samples. Initial analysis revealed that LEMD1 expression was significantly upregulated in TC tissues compared with that in normal tissues. The results of the thyroid RNA‑seq datasets from The Cancer Genome Atlas were consistent with the RNA‑seq analysis results of the present study. High LEMD1 expression increased the risk of lymph node metastasis in patients with TC. The biological function of LEMD1 on cell proliferation, migration, invasion and apoptosis was investigated in vitro via small interfering RNA and overexpression vector. Gene set enrichment analysis indicated that high LEMD1 expression was associated with epithelial‑mesenchymal transition (EMT) and the Wnt/β‑catenin signaling pathway. Western blotting revealed that LEMD1 modulated the protein expression levels of E‑cadherin, N‑cadherin, vimentin, β‑catenin and cleaved‑caspase 3. In conclusion, the present results indicated that LEMD1 may drive TC cell tumorigenesis and progression by activating the Wnt/β‑catenin signaling pathway and EMT.

View Figures

View References

1	Lloyd RV, Osamura RY, Klöppel G and Rosai J: WHO Classification of Tumours of Endocrine Organs. 4th Edition. 10. IARC Press; Lyon: 2017
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
3	Qian B, He M, Dong S, Wang J and Chen K: Incidence and mortality of thyroid cancers in Tianjin from 1981 to 2001. Chin J Endocrinol Metab. 21:432–434. 2005.
4	Sosa JA and Udelsman R: Papillary thyroid cancer. Surg Oncol Clin N Am. 15:585–601. 2006. View Article : Google Scholar : PubMed/NCBI
5	Hinson AM, Massoll NA, Jolly LA, Stack BC Jr, Bodenner DL and Franco AT: Structural alterations in tumor-draining lymph nodes before papillary thyroid carcinoma metastasis. Head Neck. 39:1639–1646. 2017. View Article : Google Scholar : PubMed/NCBI
6	Albores-Saavedra J, Henson DE, Glazer E and Schwartz AM: Changing patterns in the incidence and survival of thyroid cancer with follicular phenotype-papillary, follicular, and anaplastic: A morphological and epidemiological study. Endocr Pathol. 18:1–7. 2007. View Article : Google Scholar : PubMed/NCBI
7	LiVolsi VA: Papillary thyroid carcinoma: An update. Mod Pathol. 24 (Suppl 2):S1–S9. 2011. View Article : Google Scholar
8	Hong IK, Eun YG, Chung DH, Kwon KH and Kim DY: Association of the oncostatin m receptor gene polymorphisms with papillary thyroid cancer in the korean population. Clin Exp Otorhinolaryngol. 4:193–198. 2011. View Article : Google Scholar : PubMed/NCBI
9	Ho AS, Luu M, Barrios L, Chen I, Melany M, Ali N, Patio C, Chen Y, Bose S, Fan X, et al: Incidence and mortality risk spectrum across aggressive variants of papillary thyroid carcinoma. JAMA Oncol. 6:706–713. 2020. View Article : Google Scholar : PubMed/NCBI
10	Choden S, Keelawat S, Jung CK and Bychkov A: VE1 immunohistochemistry improves the limit of genotyping for detecting BRAF^V600E mutation in papillary thyroid cancer. Cancers (Basel). 12:5962020. View Article : Google Scholar : PubMed/NCBI
11	Levine AJ, Momand J and Finlay CA: The p53 tumour suppressor gene. Nature. 351:453–456. 1991. View Article : Google Scholar : PubMed/NCBI
12	You JS and Jones PA: Cancer genetics and epigenetics: Two sides of the same coin? Cancer Cell. 22:9–20. 2012. View Article : Google Scholar : PubMed/NCBI
13	Liz J and Esteller M: lncRNAs and microRNAs with a role in cancer development. Biochim Biophys Acta. 1859:169–176. 2016. View Article : Google Scholar : PubMed/NCBI
14	Liu Z, Hou P, Ji M, Guan H, Studeman K, Jensen K, Vasko V, El-Naggar AK and Xing M: Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab. 93:3106–3116. 2008. View Article : Google Scholar : PubMed/NCBI
15	Xing M: BRAF mutation in thyroid cancer. Endocr Relat Cancer. 12:245–262. 2005. View Article : Google Scholar : PubMed/NCBI
16	Xie H, Wei B, Shen H, Gao Y, Wang L and Liu H: BRAF mutation in papillary thyroid carcinoma (PTC) and its association with clinicopathological features and systemic inflammation response index (SIRI). Am J Transl Res. 10:2726–2736. 2018.PubMed/NCBI
17	Salvatore G, Giannini R, Faviana P, Caleo A, Migliaccio I, Fagin JA, Nikiforov YE, Troncone G, Palombini L, Basolo F and Santoro M: Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab. 89:5175–5180. 2004. View Article : Google Scholar : PubMed/NCBI
18	Lian EY, Maritan SM, Cockburn JG, Kasaian K, Crupi MJ, Hurlbut D, Jones SJ, Wiseman SM and Mulligan LM: Differential roles of RET isoforms in medullary and papillary thyroid carcinomas. Endocr Relat Cancer. 24:53–69. 2017. View Article : Google Scholar : PubMed/NCBI
19	Chang Y, Wang X, Xu Y, Yang L, Qian Q, Ju S, Chen Y, Chen S, Qin N, Ma Z, et al: Comprehensive characterization of cancer-testis genes in testicular germ cell tumor. Cancer Med. 8:3511–3519. 2019. View Article : Google Scholar : PubMed/NCBI
20	Li Q, Ge Y, Chen X, Wang L, Xia Y and Xu Z, Li Z, Wang W, Yang L, Zhang D and Xu Z: LEM domain containing 1 promotes proliferation via activating the PI3K/Akt signaling pathway in gastric cancer. J Cell Biochem. 120:15190–15201. 2019. View Article : Google Scholar : PubMed/NCBI
21	Matsuyama H, Suzuki HI, Nishimori H, Noguchi M, Yao T, Komatsu N, Mano H, Sugimoto K and Miyazono K: miR-135b mediates NPM-ALK-driven oncogenicity and renders IL-17-producing immunophenotype to anaplastic large cell lymphoma. Blood. 118:6881–6892. 2011. View Article : Google Scholar : PubMed/NCBI
22	Takeda R, Hirohashi Y, Shen M, Wang L, Ogawa T, Murai A, Yamamoto E, Kubo T, Nakatsugawa M, Kanaseki T, et al: Identification and functional analysis of variants of a cancer/testis antigen LEMD1 in colorectal cancer stem-like cells. Biochem Biophys Res Commun. 485:651–657. 2017. View Article : Google Scholar : PubMed/NCBI
23	Wang K, Singh D, Zeng Z, Coleman SJ, Huang Y, Savich GL, He X, Mieczkowski P, Grimm SA, Perou CM, et al: MapSplice: Accurate mapping of RNA-seq reads for splice junction discovery. Nucleic Acids Res. 38:e1782010. View Article : Google Scholar : PubMed/NCBI
24	van Staveren WC, Solis DW, Delys L, Duprez L, Andry G, Franc B, Thomas G, Libert F, Dumont JE, Detours V and Maenhaut C: Human thyroid tumor cell lines derived from different tumor types present a common dedifferentiated phenotype. Cancer Res. 67:8113–8120. 2007. View Article : Google Scholar : PubMed/NCBI
25	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
26	Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
27	Georgakopoulos-Soares I, Chartoumpekis DV, Kyriazopoulou V and Zaravinos A: EMT factors and metabolic pathways in cancer. Front Oncol. 10:4992020. View Article : Google Scholar : PubMed/NCBI
28	Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM and Matrisian LM: Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 74:2913–2921. 2014. View Article : Google Scholar : PubMed/NCBI
29	Lundgren CI, Hall P, Dickman PW and Zedenius J: Clinically significant prognostic factors for differentiated thyroid carcinoma: A population-based, nested case-control study. Cancer. 106:524–531. 2006. View Article : Google Scholar : PubMed/NCBI
30	Lamouille S, Xu J and Derynck R: Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 15:178–196. 2014. View Article : Google Scholar : PubMed/NCBI
31	Kang Y and Massague J: Epithelial-mesenchymal transitions: Twist in development and metastasis. Cell. 118:277–279. 2004. View Article : Google Scholar : PubMed/NCBI
32	Sasahira T, Kurihara M, Nakashima C, Kirita T and Kuniyasu H: LEM domain containing 1 promotes oral squamous cell carcinoma invasion and endothelial transmigration. Br J Cancer. 115:52–58. 2016. View Article : Google Scholar : PubMed/NCBI
33	Yuki D, Lin YM, Fujii Y, Nakamura Y and Furukawa Y: Isolation of LEM domain-containing 1, a novel testis-specific gene expressed in colorectal cancers. Oncol Rep. 12:275–280. 2004.PubMed/NCBI
34	Ghafouri-Fard S, Ousati Ashtiani Z, Sabah Golian B, Hasheminasab SM and Modarressi MH: Expression of two testis-specific genes, SPATA19 and LEMD1, in prostate cancer. Arch Med Res. 41:195–200. 2010. View Article : Google Scholar : PubMed/NCBI
35	Hirohashi Y, Torigoe T, Tsukahara T, Kanaseki T, Kochin V and Sato N: Immune responses to human cancer stem-like cells/cancer-initiating cells. Cancer Sci. 107:12–17. 2016. View Article : Google Scholar : PubMed/NCBI
36	MacDonald BT, Tamai K and He X: Wnt/beta-catenin signaling: Components, mechanisms, and diseases. Dev Cell. 17:9–26. 2009. View Article : Google Scholar : PubMed/NCBI
37	Najdi R, Proffitt K, Sprowl S, Kaur S, Yu J, Covey TM, Virshup DM and Waterman ML: A uniform human Wnt expression library reveals a shared secretory pathway and unique signaling activities. Differentiation. 84:203–213. 2012. View Article : Google Scholar : PubMed/NCBI